-
Review
-
Korean J Med. 2014;87(1):26-33. Published online July 1, 2014.
DOI: https://doi.org/10.3904/kjm.2014.87.1.26
- 새로운 항응고제의 임상적 적용: 비판막성 심방세동 환자에서
뇌졸중의 예방을 위한 새로운 항응고제의 사용을 중심으로
-
김동민, 이명용
-
단국대학교 의과대학 내과학교실
- Application of New Oral Anticoagulants: Prevention of Stroke in Patients with
Nonvalvular Atrial Fibrillation
-
Dongmin Kim, Myung-Yong Lee
-
Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea
- Corresponding author: Myung-Yong Lee ,Tel: +82-41-550-3054, Fax: +82-41-569-8122, Email: mel_lee@dankook.ac.kr
-
- Abstract
- Only anticoagulation has been shown to reduce atrial fibrillation-related deaths. Vitamin K antagonists are difficult to use due to
their narrow therapeutic range, unpredictable response, requirement for frequent coagulation monitoring, frequent dose adjustment,
slow onset-offset, and numerous drug-drug and drug-food interactions. New oral anticoagulants (NOACs), such as dabigatran,
rivaroxaban, and apixaban have been developed and are available in Korea, and edoxaban was shown to be effective and safe, also.
NOACs showed better pharmacodynamics with predictable serum concentrations and effects, and no requirement for coagulation
monitoring. These drugs have been shown to be more effective and safer than warfarin for prevention of stroke and systemic
thromboembolism in patients with nonvalvular atrial fibrillation. Broad, appropriate, and aggressive use of NOACs would improve
the results of treatment in patients with nonvalvular atrial fibrillation in Korea.
Keywords :
